BASEL, Switzerland, Feb. 15 /PRNewswire/ - Neuro-Biotech Corp. (PINKSHEET: MRES) (OTCQB: MRES). Dr. Claude Poulin CEO is pleased to announce to its shareholders that the board of directors have voted to accept the 15 cent offer. Full details will be provided to shareholders at closing of market February 15, 2011.
For more information on Neuro-Biotech Corp or to contact a company representative, please visit: www.neuro-biotechcorp.com
FORWARD LOOKING STATEMENTS
This release contains statements that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Act of 1995. Certain statements in this press release may contain words such as "anticipates," "believes," "could," "expects," "intends," "may," "projects," "targets" and other similar language that is considered forward-looking statements. These forward-looking statements are subject to certain risks and uncertainties and persons reading this release are cautioned that such statements are only predictions, and that the Company's actual future results or performance may be materially different. The Company disclaims any intention or obligation to update or revise forward-looking information, whether as a result of new information, future events, or otherwise, could cause the company's actual results to differ materially from those indicated in any forward-looking statements.
Dr. Claude Poulin
41 61 500 05 16
SOURCE Neuro-Biotech Corp.